Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications.
The basal cell carcinoma pipeline drugs market research report provides an analysis of the basal cell carcinoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases covering the product development milestones. Additionally, the report provides an overview of key players involved in therapeutic development for basal cell carcinoma and features dormant and discontinued projects.
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Targets
Some of the targets of the basal cell carcinoma pipeline drugs market Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the basal cell carcinoma pipeline drugs market are Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor, Cytotoxic To Cells Expressing Fibronectin among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the basal cell carcinoma pipeline drugs market are topical, intratumor, intravenous, oral, intralesional and subcutaneous among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Basal Cell Carcinoma Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the basal cell carcinoma pipeline drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, oncolytic virus, and enzyme including a few others.
Basal Cell Carcinoma Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the basal cell carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG among others.
Basal Cell Carcinoma Pipeline Drugs Market, by Leading Companies
Basal Cell Carcinoma Pipeline Drugs Market Report Overview
| Key Targets | Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin |
| Key Mechanisms of Action | Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor Cytotoxic To Cells Expressing Fibronectin |
| Key Routes of Administration | Topical, Intratumor, Intravenous, Oral, Intralesional and Subcutaneous |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Gene Therapy, Fusion Protein, Oncolytic Virus, and Enzyme |
| Key Companies | Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the targets of the basal cell carcinoma pipeline drugs market are Smoothened Homolog, Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, Interferon Gamma, Serine/Threonine Protein Kinase mTOR and Cells Expressing Fibronectin among others.
The key mechanism of action of the basal cell carcinoma pipeline drugs market are Smoothened Homolog Antagonist, Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Interferon Gamma Activator, Serine/Threonine Protein Kinase mTOR Inhibitor Cytotoxic To Cells Expressing Fibronectin among others.
The routes of administration in the basal cell carcinoma pipeline drugs market are topical, intratumor, intravenous, oral, intralesional and subcutaneous among others.
The molecule types in the basal cell carcinoma pipeline drugs market are small molecule, monoclonal antibody, gene therapy, fusion protein, oncolytic virus, and enzyme including a few others.
Some of the leading companies in the basal cell carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Palvella Therapeutics LLC, Transgene SA, Kintor Pharmaceutical Ltd, MediWound Ltd, Philogen SpA, AiViva BioPharma Inc, Amgen Inc, Bayer AG among others.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Oncology reports